Compare PTLO & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTLO | PRTC |
|---|---|---|
| Founded | 1963 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.0M | 464.3M |
| IPO Year | 2021 | N/A |
| Metric | PTLO | PRTC |
|---|---|---|
| Price | $5.51 | $17.64 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $8.06 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 2.5K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $732,066,000.00 | N/A |
| Revenue This Year | $9.71 | N/A |
| Revenue Next Year | $6.20 | N/A |
| P/E Ratio | $19.56 | ★ $8.09 |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $4.41 | $13.30 |
| 52 Week High | $14.47 | $20.00 |
| Indicator | PTLO | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 40.04 |
| Support Level | $5.34 | $16.55 |
| Resistance Level | $6.12 | $18.01 |
| Average True Range (ATR) | 0.33 | 0.30 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 36.27 | 0.00 |
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.